Literature DB >> 29272472

HIV Infection and Circulating Levels of Prosurfactant Protein B and Surfactant Protein D.

Meredith S Shiels1, Gregory D Kirk2, M Bradley Drummond3, Dilsher Dhillon4, Samir M Hanash4, Ayumu Taguchi5, Eric A Engels1.   

Abstract

Prosurfactant protein B (pro-SFTPB) and surfactant protein D (SFTPD) are markers of lung inflammation and damage. We estimated geometric mean pro-SFTPB and SFTPD levels in 500 human immunodeficiency virus (HIV)-infected and 300 HIV-uninfected injection drug users, adjusting for smoking and other covariates. Pro-SFTPB levels were significantly higher among people with HIV (PWH) (adjusted geometric mean, 21.4 vs 18.1 ng/mL; P = .03), and were higher with lower CD4 counts (P trend = .001), higher HIV RNA (P trend = .05), and without highly active antiretroviral therapy (P = .03). These associations were not observed for SFTPD. Serum levels of pro-SFTPB are elevated among PWH and are associated with immunosuppression and uncontrolled viremia. Published by Oxford University Press for the Infectious Diseases Society of America 2017. This work is written by (a) US Government employee(s) and is in the public domain in the US.

Entities:  

Keywords:  HIV; inflammation; lung; surfactant protein

Mesh:

Substances:

Year:  2018        PMID: 29272472      PMCID: PMC5853828          DOI: 10.1093/infdis/jix510

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   7.759


  15 in total

1.  HIV antiretroviral therapy reduces circulating surfactant protein-D levels.

Authors:  K M Kunisaki; H Quick; J V Baker
Journal:  HIV Med       Date:  2011-10       Impact factor: 3.180

2.  Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.

Authors:  Lesley S Park; Raúl U Hernández-Ramírez; Michael J Silverberg; Kristina Crothers; Robert Dubrow
Journal:  AIDS       Date:  2016-01       Impact factor: 4.177

3.  The ALIVE study, a longitudinal study of HIV-1 infection in intravenous drug users: description of methods and characteristics of participants.

Authors:  D Vlahov; J C Anthony; A Munoz; J Margolick; K E Nelson; D D Celentano; L Solomon; B F Polk
Journal:  NIDA Res Monogr       Date:  1991

4.  Understanding the clinical and economic outcomes of HIV therapy: the Johns Hopkins HIV clinical practice cohort.

Authors:  R D Moore
Journal:  J Acquir Immune Defic Syndr Hum Retrovirol       Date:  1998

5.  Circulating markers of interstitial lung disease and subsequent risk of lung cancer.

Authors:  Meredith S Shiels; Anil K Chaturvedi; Hormuzd A Katki; Bernadette R Gochuico; Neil E Caporaso; Eric A Engels
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-08-09       Impact factor: 4.254

6.  Plasma pro-surfactant protein B and lung function decline in smokers.

Authors:  Janice M Leung; John Mayo; Wan Tan; C Martin Tammemagi; Geoffrey Liu; Stuart Peacock; Frances A Shepherd; John Goffin; Glenwood Goss; Garth Nicholas; Alain Tremblay; Michael Johnston; Simon Martel; Francis Laberge; Rick Bhatia; Heidi Roberts; Paul Burrowes; Daria Manos; Lori Stewart; Jean M Seely; Michel Gingras; Sergio Pasian; Ming-Sound Tsao; Stephen Lam; Don D Sin
Journal:  Eur Respir J       Date:  2015-01-22       Impact factor: 16.671

Review 7.  HIV-associated obstructive lung diseases: insights and implications for the clinician.

Authors:  M Bradley Drummond; Gregory D Kirk
Journal:  Lancet Respir Med       Date:  2014-05-13       Impact factor: 30.700

8.  Cancer risk in HIV-infected people in the USA from 1996 to 2012: a population-based, registry-linkage study.

Authors:  Raúl U Hernández-Ramírez; Meredith S Shiels; Robert Dubrow; Eric A Engels
Journal:  Lancet HIV       Date:  2017-08-10       Impact factor: 12.767

9.  Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study.

Authors:  Jill Koshiol; Melissa Rotunno; Dario Consonni; Angela Cecilia Pesatori; Sara De Matteis; Alisa M Goldstein; Anil K Chaturvedi; Sholom Wacholder; Maria Teresa Landi; Jay H Lubin; Neil E Caporaso
Journal:  PLoS One       Date:  2009-10-08       Impact factor: 3.240

10.  HIV Impairs Lung Epithelial Integrity and Enters the Epithelium to Promote Chronic Lung Inflammation.

Authors:  Kieran A Brune; Fernanda Ferreira; Pooja Mandke; Eric Chau; Neil R Aggarwal; Franco R D'Alessio; Allison A Lambert; Gregory Kirk; Joel Blankson; M Bradley Drummond; Athe M Tsibris; Venkataramana K Sidhaye
Journal:  PLoS One       Date:  2016-03-01       Impact factor: 3.240

View more
  3 in total

1.  Short Communication: A Pilot Study of the Effects of Losartan Versus Placebo on Pneumoproteins in HIV: A Secondary Analysis of a Randomized Double Blind Study.

Authors:  David M MacDonald; Gary Collins; Chris H Wendt; Julian Wolfson; Russell P Tracy; Frank Rhame; Steven Deeks; Stacey A Rizza; Zelalem Temesgen; Caryn Morse; Angelike P Liappis; Irini Sereti; Jason V Baker; Ken M Kunisaki
Journal:  AIDS Res Hum Retroviruses       Date:  2021-04-30       Impact factor: 2.205

2.  Effect of Body Weight and Other Metabolic Factors on Risk of Non-Small Cell Lung Cancer among Veterans with HIV and a History of Smoking.

Authors:  Jose M Garcia; Jennifer R Kramer; Peter A Richardson; Sarah Ahmed; Kathryn E Royse; Donna L White; Suchismita Raychaudhury; Elaine Chang; Christine M Hartman; Michael J Silverberg; Elizabeth Y Chiao
Journal:  Cancers (Basel)       Date:  2020-12-17       Impact factor: 6.575

3.  Surfactant proteins analysis in perinatal deceased preterm twins among the Romanian population.

Authors:  Sinziana-Andra Ghitoi; Mariana Așchie; Georgeta Camelia Cozaru; Manuela Enciu; Elena Matei; Antonela-Anca Nicolau; Gabriela Izabela Bălțătescu; Nicolae Dobrin; Roxana Elena Cîrjaliu; Ariadna Petronela Fildan
Journal:  Medicine (Baltimore)       Date:  2022-07-29       Impact factor: 1.817

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.